Literature DB >> 22911331

Estimated mean sojourn time associated with hemoccult SENSA for detection of proximal and distal colorectal cancer.

Wenying Zheng1, Carolyn M Rutter.   

Abstract

BACKGROUND: Sojourn time is the length of the preclinical screen-detectable phase, a period when a test can detect asymptomatic disease. Mean sojourn time (MST) is an important factor in determining appropriate screening intervals. Available estimates of MST for colorectal cancer (CRC) are imprecise and are associated with the older Hemoccult II test. This article presents MST estimates associated with the newer Hemoccult SENSA test and describes differences in MST by the location of cancer in the colorectum and age at the time of screening.
METHODS: MST was estimated from a cohort of 42,079 patients who underwent Hemoccult SENSA between January 1, 1997 and December 31, 2010. The precision of MST estimates was improved by incorporating information from a meta-analysis of the sensitivity of Hemoccult SENSA into the analytic model.
RESULTS: Estimated MST for cancers in the proximal and distal colorectum, with 95% credible intervals (CrI) in years, were: 3.86 (1.55-6.91) and 3.35 (2.11-4.93) among 45- to 54-year olds; 3.78 (2.18-5.77) and 2.24 (1.48-3.17) among 55- to 64-year olds; and 2.70 (1.41-4.31) and 2.10 (1.34-3.04) among 65- to 74-year olds.
CONCLUSIONS: MST associated with Hemoccult SENSA was longer for CRC in the proximal versus distal colon. We found no evidence that MST increases with age and some evidence that it may decrease. IMPACT: These results add new information about the natural history of CRC and information about the performance of Hemoccult SENSA. 2012 AACR

Entities:  

Mesh:

Year:  2012        PMID: 22911331      PMCID: PMC3557510          DOI: 10.1158/1055-9965.EPI-12-0561

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  42 in total

1.  Does Medicare coverage of colonoscopy reduce racial/ethnic disparities in cancer screening among the elderly?

Authors:  Ya-Chen Tina Shih; Lirong Zhao; Linda S Elting
Journal:  Health Aff (Millwood)       Date:  2006 Jul-Aug       Impact factor: 6.301

2.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time.

Authors:  G Launoy; T C Smith; S W Duffy; V Bouvier
Journal:  Int J Cancer       Date:  1997-10-09       Impact factor: 7.396

5.  Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.

Authors:  Ludovic Barault; Céline Charon-Barra; Valérie Jooste; Mathilde Funes de la Vega; Laurent Martin; Patrick Roignot; Patrick Rat; Anne-Marie Bouvier; Pierre Laurent-Puig; Jean Faivre; Caroline Chapusot; Francoise Piard
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

6.  Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.

Authors:  James E Allison; Lori C Sakoda; Theodore R Levin; Jo P Tucker; Irene S Tekawa; Thomas Cuff; Mary Pat Pauly; Lyle Shlager; Albert M Palitz; Wei K Zhao; J Sanford Schwartz; David F Ransohoff; Joseph V Selby
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

7.  Estimating key parameters in FOBT screening for colorectal cancer.

Authors:  Dongfeng Wu; Diane Erwin; Gary L Rosner
Journal:  Cancer Causes Control       Date:  2008-08-15       Impact factor: 2.506

8.  Stool DNA and occult blood testing for screen detection of colorectal neoplasia.

Authors:  David A Ahlquist; Daniel J Sargent; Charles L Loprinzi; Theodore R Levin; Douglas K Rex; Dennis J Ahnen; Kandice Knigge; M Peter Lance; Lawrence J Burgart; Stanley R Hamilton; James E Allison; Michael J Lawson; Mary E Devens; Jonathan J Harrington; Shauna L Hillman
Journal:  Ann Intern Med       Date:  2008-10-07       Impact factor: 25.391

9.  Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasia.

Authors:  D J St John; G P Young; J G McHutchison; M C Deacon; M A Alexeyeff
Journal:  Ann Intern Med       Date:  1992-09-01       Impact factor: 25.391

10.  Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data.

Authors:  Byron C Wallace; Christopher H Schmid; Joseph Lau; Thomas A Trikalinos
Journal:  BMC Med Res Methodol       Date:  2009-12-04       Impact factor: 4.615

View more
  4 in total

1.  Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.

Authors:  Ayush Sharma; Thomas C Smyrk; Michael J Levy; Mark A Topazian; Suresh T Chari
Journal:  Gastroenterology       Date:  2018-04-30       Impact factor: 22.682

2.  Symptom lead times in lung and colorectal cancers: what are the benefits of symptom-based approaches to early diagnosis?

Authors:  M Biswas; A E Ades; W Hamilton
Journal:  Br J Cancer       Date:  2014-12-02       Impact factor: 7.640

3.  Interval cancers in a population-based screening program for colorectal cancer in catalonia, Spain.

Authors:  M Garcia; X Domènech; C Vidal; E Torné; N Milà; G Binefa; L Benito; V Moreno
Journal:  Gastroenterol Res Pract       Date:  2015-02-24       Impact factor: 2.260

4.  CMOST: an open-source framework for the microsimulation of colorectal cancer screening strategies.

Authors:  Meher K Prakash; Brian Lang; Henriette Heinrich; Piero V Valli; Peter Bauerfeind; Amnon Sonnenberg; Niko Beerenwinkel; Benjamin Misselwitz
Journal:  BMC Med Inform Decis Mak       Date:  2017-06-05       Impact factor: 2.796

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.